Intravacc B.V.
Bilthoven, UT
- UEI
- RY3NEWMNZA63
- CAGE
- H2MN6
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, Netherlands
- Website
- intravacc.nl
- Founded
- 2013
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$964,757 |
| FY2025 | $2,032,481 |
| FY2024 | $2,674,055 |
| FY2023 | $1,842,639 |
Contract awards
Similar vendors
About the company
Intravacc B.V. is a foreign-owned, for-profit corporate entity based in the Netherlands that specializes in developing next generation vaccines. According to its website, Intravacc acts as a bridge between discovery and pilot scale biomanufacturing, offering vaccine platforms and services to help reduce human diseases.
Intravacc has received prime federal contract awards from the Department of Health and Human Services' National Institutes of Health and the National Institute of Allergy and Infectious Diseases totaling over $24 million. In 2022, Intravacc was awarded a $14.6 million definitive cost-no-fee contract to develop an intranasal vaccine against gonorrhea using outer membrane vesicles combined with sustained-release microspheres containing recombinant human interleukin-12. This work is being performed through 2026 under the NIAID's Omnibus Broad Agency Announcement seeking vaccine candidates against priority pathogens. In 2020, Intravacc received a $9.4 million definitive contract to develop an intramuscular inactivated whole virus vaccine through a Phase I clinical trial to induce protection against Enterovirus D68 induced Acute Flaccid Myelitis, with work extending until 2026. Intravacc has also served as a sub-contractor to Trustees of Boston University on a project related to developing a vaccine for gonorrhea prevention. No set-aside designations were applied to Intravacc's prime contract awards from NIH and NIAID.
Quick answers
Is Intravacc B.V. registered in SAM.gov?
Yes. Intravacc B.V.'s SAM.gov registration is active through January 19, 2027.
How much has Intravacc B.V. received in federal contracts?
Federal contracts obligated $2,032,481 to Intravacc B.V. in fiscal year 2025 and $5,584,418 in fiscal years 2023 through 2027.
What is Intravacc B.V.'s most recent federal award?
Intravacc B.V.'s most recent federal contract award is Development of an intranasal vaccine against gonorrhea based on outer membrane vesicles combined with sustained-release… (75N93022C00058), from National Institute of Allergy and Infectious Diseases (NIH), on September 21, 2022.
On GovTribe
See Intravacc B.V.'s full federal record
- Federal contract awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors